G&E Herbal Biotechnology Co., Ltd. (4911) AI Stock Analysis

G&E Herbal Biotechnology Co., Ltd.

(TPEx:4911)

Select Model

Rating:72Outperform

Price Target:TWD 28.00▲(10.67% Upside)

Action:initiatedcoverage

Date:11/09/26

The score is driven primarily by robust fundamentals: consistent revenue growth, exceptional margins (84% gross, 45% net), rising returns on equity, and an essentially debt-free balance sheet that leaves minimal financial risk. Valuation adds support, with a moderate 18.7 P/E and an attractive 4.66% dividend yield. The main drags are the deteriorating technical picture — the stock sits below all key moving averages with a negative MACD — and weakening cash conversion, where operating cash flow covered only half of reported net income. Decelerating growth off a small revenue base is a further consideration, though oversold momentum readings suggest the selling pressure may be nearing exhaustion.

Positive Factors

Strong ProfitabilityThe shift from losses in 2020–2021 to substantial profits from 2022 onward indicates a meaningful improvement in operating economics. High gross, net, and operating margins provide an earnings base that can support reinvestment and resilience over the next several quarters.

Negative Factors

Sharp Revenue ContractionThe abrupt 2025 revenue contraction undermines confidence in demand stability and makes recent earnings harder to forecast. If lower sales persist, fixed operating resources and the company’s small scale could reduce margin durability despite currently strong profitability.

G&E Herbal Biotechnology Co., Ltd. (4911) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.72B
Dividend Yield: 4.61%
Average Volume (3M): 21.54K
Price to Earnings (P/E): 18.9
Beta (1Y): 0.16
Revenue Growth: -26.73%
EPS Growth: -34.96%
Country: TW
Employees: 38
Sector: General
Sector Strength: 55
Industry: Biotechnology

G&E Herbal Biotechnology Co., Ltd. Business Overview & Revenue Model

Company Description

G&E Herbal Biotechnology Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the innovation and commercialization of advanced botanical extraction technologies and the products derived from them. Its diverse portfolio features a ra...

G&E Herbal Biotechnology Co., Ltd. Financial Statement Overview

Summary

G&E Herbal shows a very strong financial profile: revenue grew to NT$309.1 million (up ~24% year-over-year) with gross margin above 80%, operating margin near 49% and net margin of 45%, while net income rose 36% to NT$139.2 million. The balance sheet is a standout strength — effectively debt-free with equity funding ~95% of assets and return on equity improving for four straight years to 15%. Offsetting this, cash flow weakened materially: operating cash flow fell to NT$70.2 million from NT$134.7 million and covered only about half of net income, pointing to working capital build-up. Growth is also decelerating from earlier explosive rates on a small absolute revenue base.

Income Statement

85Very Positive

Balance Sheet

90Very Positive

Cash Flow

66Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	215.61M	309.13M	249.03M	181.44M	64.61M	24.57M
Gross Profit	170.85M	259.60M	205.34M	144.59M	39.35M	9.63M
EBITDA	94.41M	162.91M	135.15M	99.84M	16.63M	-10.22M
Net Income	86.25M	139.20M	102.06M	72.40M	7.38M	-19.88M
Balance Sheet
Total Assets	977.35M	975.22M	959.17M	883.10M	782.77M	692.13M
Cash, Cash Equivalents and Short-Term Investments	425.82M	430.31M	408.87M	312.92M	205.95M	108.88M
Total Debt	5.00M	6.96M	8.09M	5.43M	6.39M	2.62M
Total Liabilities	100.81M	47.15M	125.64M	119.86M	91.94M	8.68M
Stockholders Equity	876.54M	928.07M	833.53M	763.24M	690.84M	683.45M
Cash Flow
Free Cash Flow	19.16M	66.97M	128.68M	107.96M	97.00M	-11.18M
Operating Cash Flow	22.11M	70.18M	134.68M	113.48M	99.96M	-9.19M
Investing Cash Flow	67.05M	-98.81M	-89.24M	-88.43M	2.50M	7.01M
Financing Cash Flow	-46.59M	-45.53M	-32.54M	-116.00K	0	0

G&E Herbal Biotechnology Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4911 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4111	76Outperform	TWD 1.71B	9.16	―	4.56%	5.33%	13.75%
TW:4911	72Outperform	TWD 1.74B	18.88	―	4.61%	-26.73%	-34.96%
TW:1294	67Neutral	TWD 1.62B	10.44	―	6.73%	20.43%	4.47%
TW:4148	60Neutral	TWD 1.96B	10.80	―	3.42%	15.66%	31.51%
TW:1295	59Neutral	TWD 1.57B	10.01	―	7.16%	-5.28%	-27.33%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4127	40Underperform	TWD 1.65B	23.58	―	―	52.12%	―

* General Sector Average

Performance Comparison

TW:4911 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4911	G&E Herbal Biotechnology Co., Ltd.	25.30	-18.34	-42.03%
TW:1294	Hantech Bio-Technology Co., Ltd.	44.55	-13.99	-23.89%
TW:1295	Synbio Tech Inc	41.80	-54.05	-56.39%
TW:4111	Chi Sheng Pharma & Biotech Co., Ltd.	28.50	-0.44	-1.53%
TW:4127	Tien Liang Biotech Co., Ltd.	36.15	5.35	17.37%
TW:4148	All Cosmos Bio-Tech Holding Corp.	29.20	-10.45	-26.36%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

G&E Herbal Biotechnology Co., Ltd. AI Stock Analysis